IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. And Reminds Investors With Losses To Contact The Firm

LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC announces a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company") (Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 3, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016, lead plaintiff motion deadline.

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at [email protected].

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, Immunomedics issued false and misleading statements to investors and/or failed to disclose: that the Company’s abstract for antibody-drug IMMU-132 submitted to the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting contained previously disclosed results from a mid-stage study; that Immunomedics misrepresented to ASCO that the abstract contained only updated and previously undisclosed data; and that as a result of this ASCO removed the IMMU-132 presentation from the 2016 ASCO Annual Meeting schedule.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160623006419/en/

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]

Source: Lundin Law PC

You May Also Be Interested In

• NorthStar Appoints Peter Pfreundschuh to Board of Managers
• Beam Global to Release 2023 Operating Results, Conference Call Scheduled for April 17, 2024 at 4:30 p.m. ET
• Northern Dynasty: USACE Updates the Pebble Permitting Process in Light of the EPA Veto